Guardant Health (GH) Stock Overview
A precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
GH Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Guardant Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$167.98 |
| 52 Week High | US$172.61 |
| 52 Week Low | US$40.36 |
| Beta | 1.59 |
| 1 Month Change | 32.24% |
| 3 Month Change | 79.03% |
| 1 Year Change | 232.63% |
| 3 Year Change | 351.68% |
| 5 Year Change | 35.59% |
| Change since IPO | 421.68% |
Recent News & Updates
Recent updates
Narrative Update • Jun 25
GH: Future Returns Will Depend On Executing Expanded Screening And Therapy Selection Approvals
Guardant Health’s analyst-derived fair value estimate has shifted higher to about $143 from roughly $136, as analysts factor in recent price target increases tied to FDA approvals for Guardant360 Liquid CDx and G360 CDx, Shield’s inclusion in updated screening guidelines, and what they view as stronger long-term growth and profitability potential for the company’s testing portfolio. Analyst Commentary Recent research on Guardant Health points to a cluster of higher price targets and constructive views on its testing portfolio, particularly around Guardant360 Liquid CDx, G360 CDx, and Shield.Narrative Update • Jun 04
GH: Future Returns Will Hinge On Executing Guideline Supported Screening Expansion
Guardant Health's analyst fair value estimate edges up from $128.33 to $135.76 as analysts lift price targets into the $150 to $160 range, citing higher expected G360 pricing, established test assets with favorable pricing, and potential contribution from Guardant Shield following its inclusion in updated colon cancer screening guidelines. Analyst Commentary Bullish analysts are generally focused on higher test pricing, guideline support for Guardant Shield, and the breadth of the testing portfolio as key inputs to their fair value work.Seeking Alpha • May 15
Guardant Health: Reveal And Shield Driving The Next Growth Phase
Summary Guardant Health, Inc. delivered strong results in the first quarter, with accelerating revenue growth supported by the MRD and screening businesses. GH's Quest Diagnostics partnership, product upgrades, and expanded reimbursement are set to sustain strong fundamentals and revenue diversification. While Guardant's losses are still sizeable, the company is on a clear path to profitability, driven by the scaling on the MRD and screening businesses. Strong growth and moderating losses should see Guardant's stock continue to perform well going forward. Read the full article on Seeking AlphaNarrative Update • Apr 27
GH: Future Upside Will Depend On Executing 2026 Screening Expansion
Analysts have trimmed their average price target for Guardant Health by about $1 to roughly $128. This reflects slightly more conservative fair value and P/E assumptions, even as they continue to cite strong execution across therapy selection, MRD and screening, along with an improving balance sheet, as key supports for the updated outlook.Narrative Update • Apr 11
GH: Future Upside Will Depend On Executing 2026 Screening Rollout
Analysts have trimmed the Guardant Health fair value estimate by about $1 to $129.73, reflecting a modest recalibration of long term growth and margin assumptions, even as many recent Street price targets have moved higher on stronger execution and an improved balance sheet. Analyst Commentary Street research on Guardant Health over the recent period has generally leaned constructive, with many firms lifting price targets into a broad range of roughly US$110 to US$150 and highlighting both execution and long term growth opportunities.Narrative Update • Mar 26
GH: Future Upside Will Depend On Executing 2026 Screening Expansion
Guardant Health's blended analyst price target is now aligned around $130, as multiple firms raised targets into a roughly $110 to $150 range. They cited strong recent execution, momentum across therapy selection, MRD and screening, and 2026 guidance that analysts view as supported by prior launches and an improved balance sheet.Narrative Update • Mar 10
GH: Future Upside Will Depend On Executing 2026 Screening Rollout
Guardant Health's analyst fair value estimate edges up by about $0.43 per share, as analysts factor in Street price target increases into the $110 to $150 range, along with commentary on strong execution across core franchises, updated 2026 guidance, and a series of recent product launches and approvals. Analyst Commentary Recent Street research on Guardant Health clusters around a generally constructive view, with price targets broadly in the US$110 to US$150 range and several firms updating their models after quarterly results and new 2026 guidance.Narrative Update • Feb 24
GH: Future Upside Will Hinge On Executing 2026 Screening Expansion
Our updated fair value estimate for Guardant Health has moved to $132.13 from $125.24, reflecting a series of higher Street price targets in the roughly $110 to $150 range as analysts highlight stronger revenue assumptions, solid 2026 guidance, and broad momentum across therapy selection, MRD, and screening. Analyst Commentary Street research on Guardant Health has clustered around higher fair value assumptions, with a series of price target increases in the roughly US$110 to US$150 range.Narrative Update • Feb 09
GH: Future Upside Will Hinge On 2026 Execution And Patent Resolution
Narrative Update: Guardant Health Analysts have lifted their price targets on Guardant Health, helping nudge the modeled fair value from about $121.19 to $125.24. This update is supported by views of steady revenue growth, a slightly higher assumed P/E multiple, and revised expectations for margins and discount rates following recent research from UBS, Guggenheim, Leerink, Stifel, and TD Cowen.Narrative Update • Jan 26
GH: Future Returns Will Depend On 2026 Execution And Patent Risk
Narrative Update on Guardant Health Analysts have nudged their price targets higher on Guardant Health, with our fair value estimate shifting from about US$118.18 to US$121.19 as they factor in stronger volume and pricing expectations for 2026, as well as potential publication and reimbursement catalysts that they believe could keep investor interest supported. Analyst Commentary Recent Street research has centered on higher price targets and updated views on Guardant Health following quarterly results, court developments, and sector wide revisions.Narrative Update • Jan 09
GH: Future Returns Will Depend On Sustained Progress Toward 2028 Goals
Narrative Update: Guardant Health Analyst Price Target Shift The updated fair value estimate for Guardant Health has risen from about US$112 to roughly US$118. This reflects analysts' higher price targets in the US$100 to US$130 range after recent Q3 results, a sector Q4 preview, and commentary around the company's path toward its 2028 goals.Narrative Update • Dec 22
GH: Future Upside Will Depend On Achieving Raised 2028 Revenue Milestone
The analyst price target for Guardant Health has been raised to approximately $112 from about $101, as analysts highlight stronger long term revenue growth, modestly improved profitability, and a richer valuation multiple supported by broad based target hikes following upbeat quarterly results and an encouraging outlook from the recent analyst day. Analyst Commentary Recent Street research has been overwhelmingly positive, with a series of target price increases and rating upgrades reflecting greater confidence in Guardant Health's long term growth trajectory, margin expansion potential, and execution against its 2028 financial goals.Narrative Update • Dec 08
GH: Future Upside Will Depend On Executing 2028 Revenue And Cash Flow Plan
The analyst price target for Guardant Health has been raised from $99 to about $101, as analysts point to a series of upward target revisions across the Street. These are driven by stronger than expected revenue momentum, expanding long term growth forecasts, and increased confidence in the company’s ability to reach its 2028 financial objectives.Narrative Update • Nov 24
GH: Future Upside Will Depend On Achieving 2028 Financial And Execution Goals
Analysts have raised their price target for Guardant Health from approximately $93.82 to $99.00. They cite stronger sales performance, higher future growth expectations, and widening profit margins as key drivers behind the updated outlook.Narrative Update • Nov 05
GH: Future Performance Will Hinge On Delivering Against Elevated 2028 Ambitions
Analysts have raised their price target for Guardant Health significantly, increasing it from $69.55 to $93.82. They cite strong recent sales performance as well as improved outlooks for long-term revenue growth and margin expansion.Analysis Article • Nov 02
Earnings Update: Guardant Health, Inc. (NASDAQ:GH) Just Reported And Analysts Are Boosting Their Estimates
Guardant Health, Inc. ( NASDAQ:GH ) investors will be delighted, with the company turning in some strong numbers with...Analysis Article • Oct 31
Guardant Health, Inc. (NASDAQ:GH) Stocks Shoot Up 48% But Its P/S Still Looks Reasonable
Guardant Health, Inc. ( NASDAQ:GH ) shares have continued their recent momentum with a 48% gain in the last month...Narrative Update • Oct 22
Analysts Raise Guardant Health Price Targets Amid Optimism and Cautious Growth Outlook
Guardant Health’s analyst price target has been revised upward by $1.32 to $69.55, as analysts cite ongoing improvements in revenue growth, operating margins, and business momentum across the company’s oncology and screening segments. Analyst Commentary Recent analyst reports following Guardant Health’s latest business and financial updates reflect significant optimism regarding the company’s near- and long-term prospects, with upward revisions to both price targets and financial guidance.Narrative Update • Oct 08
AI And Blood Diagnostics Will Transform Early Cancer Detection
Guardant Health's analyst price target has been raised from approximately $62 to $68 per share. Analysts cite accelerating revenue growth, improved operating margins, and ongoing commercial and strategic momentum as key factors behind the upward revision.Narrative Update • Sep 23
AI And Blood Diagnostics Will Transform Early Cancer Detection
Guardant Health’s price target was raised as analysts cited strong revenue momentum, clinical data underscoring leadership in liquid biopsy, and Q2 outperformance across key segments, resulting in a new consensus price target of $62.41. Analyst Commentary Bullish analysts cite strong revenue momentum, with new products and expanded indications expected to drive 30% annual growth through 2028, outpacing peers.Shareholder Returns
| GH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 12.6% | 5.5% | 1.6% |
| 1Y | 232.6% | 28.3% | 21.1% |
Return vs Industry: GH exceeded the US Healthcare industry which returned 28.3% over the past year.
Return vs Market: GH exceeded the US Market which returned 21.1% over the past year.
Price Volatility
| GH volatility | |
|---|---|
| GH Average Weekly Movement | 9.3% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2,498 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults.
Guardant Health, Inc. Fundamentals Summary
| GH fundamental statistics | |
|---|---|
| Market cap | US$22.30b |
| Earnings (TTM) | -US$433.19m |
| Revenue (TTM) | US$1.08b |
20.6x
P/S Ratio-51.4x
P/E RatioIs GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GH income statement (TTM) | |
|---|---|
| Revenue | US$1.08b |
| Cost of Revenue | US$379.20m |
| Gross Profit | US$701.01m |
| Other Expenses | US$1.13b |
| Earnings | -US$433.19m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.27 |
| Gross Margin | 64.90% |
| Net Profit Margin | -40.10% |
| Debt/Equity Ratio | -830.3% |
How did GH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/03 01:32 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guardant Health, Inc. is covered by 33 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Charles Albert Dillard | Bernstein |